SCHEMBL7644908

SCHEMBL7644908

C=CC(NC1CCN(C(=O)OC(C)(C)C)CC1)C(=O)OCc1ccc([N+](=O)[O-])cc1

nearest known ligand 0.48

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.48
MAPT P10636 4/20 0.48
LMNA P02545 1/20 0.48
L3MBTL1 Q9Y468 2/20 0.44
MAPK1 P28482 3/20 0.42
NPC1 O15118 1/20 0.42
HTT P42858 1/20 0.42
RAB9A P51151 1/20 0.42
NPSR1 Q6W5P4 2/20 0.41
NTSR1 P30989 1/20 0.41
CCR5 P51681 4/20 0.40
MEN1 O00255 1/20 0.40
POLB P06746 1/20 0.40
KMT2A Q03164 1/20 0.40
GPR119 Q8TDV5 2/20 0.40
YAP1 P46937 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7136587 0.87 L3MBTL1 (0.53) ALDH1A1MAPTL3MBTL1MAPK1NPC1
Hydrochloric Acid SCHEMBL7643194 0.80 TGM2 (0.39) ALDH1A1MAPTHTTRAB9AKMT2A
SCHEMBL27706952 0.80 SIGMAR1 (0.59) ALDH1A1MAPTLMNAL3MBTL1MAPK1
SCHEMBL7644917 0.79 ALDH1A1 (0.48) ALDH1A1MAPTLMNAL3MBTL1MAPK1
SCHEMBL5724167 0.79 ALDH1A1 (0.67) ALDH1A1MAPTLMNAMEN1KMT2A
SCHEMBL5012643 0.78 ALDH1A1 (0.58) ALDH1A1MAPTLMNAL3MBTL1MAPK1
SCHEMBL4024599 0.78 CCR5 (0.60) CCR5
SCHEMBL7463367 0.77 ALDH1A1 (0.48) ALDH1A1MAPTLMNAL3MBTL1GPR119
SCHEMBL8449178 0.77 ALDH1A1 (0.48) ALDH1A1MAPTLMNAL3MBTL1GPR119
SCHEMBL8094828 0.75 ALDH1A1 (0.45) ALDH1A1MAPTLMNAL3MBTL1CCR5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6476054-B1 Cyclic amine modulators of chemokine receptor activity MERCK & CO., INC. 2002-11-05 US disclosed
US-6140349-A FOR PROPHYLAXIS AND THERAPY OF HUMAN IMMUNODEFICIENCY VIRUS(HIV) INFECTIONS AND ACQUIRED IMMUNODEDICIENCY SYNDROME MERCK & CO., INC. (US) 2000-10-31 US disclosed